Sunbelt Securities Inc. Buys 300 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

Sunbelt Securities Inc. boosted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 11.3% during the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,955 shares of the company’s stock after purchasing an additional 300 shares during the quarter. Sunbelt Securities Inc.’s holdings in CRISPR Therapeutics were worth $139,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Wealth Enhancement Advisory Services LLC lifted its position in shares of CRISPR Therapeutics by 133.5% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 31,898 shares of the company’s stock worth $1,723,000 after buying an additional 18,239 shares in the last quarter. Blue Trust Inc. raised its holdings in shares of CRISPR Therapeutics by 2,932.7% during the 2nd quarter. Blue Trust Inc. now owns 1,486 shares of the company’s stock worth $80,000 after acquiring an additional 1,437 shares in the last quarter. Raymond James & Associates raised its holdings in shares of CRISPR Therapeutics by 10.0% during the 2nd quarter. Raymond James & Associates now owns 38,433 shares of the company’s stock worth $2,076,000 after acquiring an additional 3,479 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in shares of CRISPR Therapeutics by 107.4% during the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 35,001 shares of the company’s stock valued at $1,890,000 after acquiring an additional 18,125 shares during the last quarter. Finally, Carnegie Investment Counsel grew its holdings in shares of CRISPR Therapeutics by 51.0% in the second quarter. Carnegie Investment Counsel now owns 102,112 shares of the company’s stock valued at $5,515,000 after purchasing an additional 34,500 shares in the last quarter. Institutional investors own 69.20% of the company’s stock.

Insider Buying and Selling

In other news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now directly owns 62,597 shares of the company’s stock, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Samarth Kulkarni sold 30,000 shares of the firm’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the sale, the chief executive officer now directly owns 196,540 shares in the company, valued at approximately $10,931,554.80. The trade was a 13.24 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 50,382 shares of company stock valued at $2,744,179 over the last three months. 4.10% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

CRSP has been the topic of a number of recent research reports. Chardan Capital reaffirmed a “buy” rating and set a $94.00 price target on shares of CRISPR Therapeutics in a research note on Tuesday, December 10th. Barclays lowered their price target on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a report on Wednesday, November 6th. Royal Bank of Canada restated a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Wednesday. Finally, Needham & Company LLC restated a “buy” rating and set a $84.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $77.93.

CRISPR Therapeutics Stock Performance

CRISPR Therapeutics stock opened at $43.78 on Friday. The company has a market capitalization of $3.74 billion, a PE ratio of -15.47 and a beta of 1.62. The company has a 50 day moving average price of $48.79 and a 200-day moving average price of $51.19. CRISPR Therapeutics AG has a fifty-two week low of $42.86 and a fifty-two week high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The business had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. During the same period in the previous year, the company posted ($1.41) EPS. On average, analysts forecast that CRISPR Therapeutics AG will post -5.13 earnings per share for the current year.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.